Effect of Nicergoline for chronic cerebrovascular insufficiency: a meta analysis
10.3760/cma.j.issn.0254-9026.2015.10.025
- VernacularTitle:尼麦角林治疗慢性脑血管功能不全的系统评价
- Author:
Yujuan JIA
;
Yuli HOU
;
Jingtian HOU
- Publication Type:Journal Article
- Keywords:
Ergolines;
Cerebrovascular disorders;
Meta-analysis
- From:
Chinese Journal of Geriatrics
2015;34(10):1141-1144
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically review the efficacy and safety of nicergoline on chronic cerebrovascular insufficiency (CCVI).Methods Databases including the Cochrane Library,PubMed,CNKI,VIP and WanFang Date were electronically searched for relevant randomized controlled trails (RCTs) which studied the effectiveness and safety of Nicergoline on chronic cerebrovascular insufficiency.Two reviewers independently screened literature according to the inclusion and exclusion criteria,extracted data,and assessed the methodological quality.Metaanalysis was performed by using RevMan 5.2 software.Results Totally 9 studies involving 1 030 patients were included.The meta-analysis results showed that,compared with conventional treatment alone,the Nicergoline group was superior in improving the velocity of middle cerebral artery(MCA) in both systolic(MD=16.43,95％CI:10.39-22.46) and the late diastolic (MD=11.48,95％CI:5.34-17.63).Besides,Nicergoline significantly improved the pulse index (PI) of MCA (MD=-0.37,95％CI:-0.48--0.26).Likewise,it obviously improved the velocity in both systolic (MD=11.23,95％CI:6.10-16.35),the late diastolic (MD=8.80,95％CI:5.20-12.40) and the PI of vertebral artery (VA) (MD=-0.38,95％CI:-0.47--0.28).The remission rate of the nicergolinegroup was higher than that of the control group (OR=3.93,95％ CI:2.66-5.81).Drug-related adverse reactions were not reported in included studies.Conclusions Nicergoline shows a certain efficacy on CCVI without obvious adverse reactions.
